Assessments for high dose radionuclide therapy treatment planning

Radiation Protection Dosimetry

Volumn 105, Issue 1-4, 2003, Pages 581-586

  Fisher, D R ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; HOLMIUM; HOLMIUM 166; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BC8; MONOCLONAL ANTIBODY C2B8; MONOCLONAL ANTIBODY NRLU 10; PEPTIDE; PHOSPHONIC ACID DERIVATIVE; RADIOISOTOPE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

BIOTECHNOLOGY; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLON CANCER; COMPUTER PROGRAM; DOSIMETRY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG TARGETING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGE ANALYSIS; INDIVIDUALIZATION; INTESTINE; ISOTOPE LABELING; KIDNEY; LEUKEMIA; LIVER; LUNG; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ORGAN DISTRIBUTION; RADIOIMMUNOTHERAPY; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TREATMENT PLANNING; UNITED STATES; WHOLE BODY RADIATION;

EID: 0141787066     PISSN: 01448420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.rpd.a006307     Document Type: Review

References (13)

1. Raubitschek, A. Phase I/II trial of escalating Zevalin in combination with high-dose etoposide and cyclophospamide followed by autologous stem cell transplant (ASCT) for patients with poor risk/relapsed B-cell NHL. Zevalin Investigators Newsletter 1(1), 1 (IDEC Pharmaceuticals, 1 August 2002).
2. Press, O. W., and 18 others. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantion for relapsed B-cell lymphomas. Blood 96, 2934-2941 (2000).
3. Matthews, D. C. and 10 others. Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94(4), 1237-1247 (1999).
4. Weiden, P. L., Breitz, H. B., Press, O., Appelbaum, J. W., Bryan, J. K., Gaffigan, S., Stone, D., Axworthy, D., Fisher, D. R. and Reno, J. Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother. Radiopharm. 15(1), 15-29 (2000).
5. Knox, S. J., and 13 others. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 6, 406-414 (2000).
6. Eary, J., Rajendran, J., Bensinger, W. I., Girault, S., Champlin, R., Thoelke, K. and Bryan, J. K. Holmium-166 with melphalan and total body irradiation (TBI) as a preparative regimen for autologous stem cell transplantation. Proc. Chemotherapy Foundation Symposium XIX, 8-11 November 2000, New York, NY.
7. Bayouth, J., Macey, D. and Kasi, L. Pharmacokinetics, dosimetry and toxicity of holmium-166 DOTMP for bone marrow ablation in multiple myeloma. J. Nucl. Med. 36, 730 (1995).
8. Bensinger, W., Giralt, S. and Eary, J. Phase I/II study of holmium-166-DOTMP in combination with melphalan and total body irradiation with autologous peripheral blood stem cell transplant for patients with multiple Myeloma. Proc. Am. Soc. Clin. Oncol. 19(26), 9a (2000).
9. Loevinger, R., Budinger, T. F. and Watson, E. E. MIRD primer for absorbed dose calculations. ISBN 0-932004-38-5, rev. ed. (New York: The Society of Nuclear Medicine) (1991).
10. ICRP. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18(1-4) (Oxford: Pergamon) (1988).
11. Siegel, J. A., Thomas, S. R. and Stubbs, J. B. MIRD pamphlet no 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J. Nucl. Med. 40, 37S-61S (1999).
12. Stabin, M. G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 37, 538-546 (1996).
13. Fisher, D. R. Internal dosimetry for systemic radiation therapy. Semin. Radiat. Oncol. 10(2), 123-132 (2000).